Bruno Alexander Rodriguez-Rodriguez

Mr. Bruno Alexander Rodriguez-Rodriguez


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
BRBruno Alexander Rodriguez-Rodriguez
Bruno Alexander Rodriguez-Rodriguez
MNMaria Gabriela Noval
Maria Gabriela Noval
MKMaria E. Kaczmarek
Maria E. Kaczmarek
KJKyung Ku Jang
Kyung Ku Jang
STSara A. Thannickal
Sara A. Thannickal
Kenneth A. StaplefordKenneth A. Stapleford
Kenneth A. Stapleford
Epidemic RNA viruses seem to arise year after year leading to countless infections and devastating disease. SARS-CoV-2 is the most recent of these viruses, but there will undoubtedly be more to come. While effective SARS-CoV-2 vaccines are being deployed, one approach that is still missing is effective antivirals that can be used at the onset of infections and therefore prevent pandemics. Here, we screened FDA-approved compounds against SARS-CoV-2. We found that atovaquone, a pyrimidine biosynthesis inhibitor, is able to reduce SARS-CoV-2 infection in human lung cells. In addition, we found that berberine chloride, a plant-based compound used in holistic medicine, was able to inhibit SARS-CoV-2 infection in cells through direct interaction with the virion. Taken together, these studies highlight potential avenues of antiviral development to block emerging viruses. Such proactive approaches, conducted well before the next pandemic, will be essential to have drugs ready for when the next emerging virus hits.

16 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMaria G. Noval
Maria G. Noval
MKMaria Kaczmarek
Maria Kaczmarek
AKAkiko Koide
Akiko Koide
BRBruno Alexander Rodriguez-Rodriguez
Bruno Alexander Rodriguez-Rodriguez
PLPing Louie
Ping Louie
Kenneth A. StaplefordKenneth A. Stapleford
Kenneth A. Stapleford
Understanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Here, we determine the ability of sera from 101 recovered healthcare workers to neutralize both authentic SARS-CoV-2 and SARS-CoV-2 pseudotyped virus and address their antibody titers against SARS-CoV-2 nucleoprotein and spike receptor-binding domain. Interestingly, the majority of individuals have low neutralization capacity and only 6% of the healthcare workers showed high neutralizing titers against both authentic SARS-CoV-2 virus and the pseudotyped virus. We found the antibody response to SARS-CoV-2 infection generates antigen-specific isotypes as well as a diverse combination of antibody isotypes, with high titers of IgG, IgM and IgA against both antigens correlating with neutralization capacity. Importantly, we found that neutralization correlated with antibody titers as quantified by ELISA. This suggests that an ELISA assay can be used to determine seroneutralization potential. Altogether, our work provides a snapshot of the SARS-CoV-2 neutralizing antibody response in recovered healthcare workers and provides evidence that possessing multiple antibody isotypes may play an important role in SARS-CoV-2 neutralization.